Last reviewed · How we verify
Heparin - Therapeutic dosage
Heparin inhibits blood coagulation by potentiating antithrombin III, which inactivates thrombin and other clotting factors.
Heparin inhibits blood coagulation by potentiating antithrombin III, which inactivates thrombin and other clotting factors. Used for Prevention and treatment of venous thromboembolism, Acute coronary syndrome, Atrial fibrillation with thromboembolism risk.
At a glance
| Generic name | Heparin - Therapeutic dosage |
|---|---|
| Sponsor | University of Sao Paulo |
| Drug class | Anticoagulant |
| Target | Antithrombin III (indirect); Thrombin and Factor Xa (downstream targets) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Heparin is an anticoagulant that works by binding to and enhancing the activity of antithrombin III, a natural inhibitor of coagulation. This complex rapidly inactivates thrombin (Factor IIa) and Factor Xa, preventing the formation of fibrin clots. Heparin is used therapeutically to prevent and treat thrombotic events.
Approved indications
- Prevention and treatment of venous thromboembolism
- Acute coronary syndrome
- Atrial fibrillation with thromboembolism risk
- Prevention of thrombosis during hemodialysis
Common side effects
- Bleeding
- Thrombocytopenia
- Heparin-induced thrombocytopenia (HIT)
- Osteoporosis (with prolonged use)
- Hyperkalemia
- Injection site reactions
Key clinical trials
- Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in Infertility
- Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
- Heparin for RAO Post-Transradial Angiography in AIS (PHASE3)
- Timing of Venous Thromboembolism Prophylaxis in Patients With Hypertensive Intracerebral Hemorrhage (NA)
- The Intensive Care Platform Trial (PHASE4)
- Prostate Stereotactic Radiation and Radio-induced Lymphocyte Apoptosis for Predicting Late Toxicities in Prostate Cancer (PROSTERA) (NA)
- Impact of CRRT on Serum Carnitine and Micronutrient Levels
- Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Heparin - Therapeutic dosage CI brief — competitive landscape report
- Heparin - Therapeutic dosage updates RSS · CI watch RSS
- University of Sao Paulo portfolio CI